Sunday November 23, 2014




Home »  News »  Health

Nova Scotia government expanding coverage for retinal disease treatments

HALIFAX - The Nova Scotia government says two new groups of patients with chronic retina disease will now have certain treatments covered under the provincial drug program.

Health and Wellness Minister Leo Glavine says people with diabetic macular edema and retinal vein occlusion will be covered for Lucentis and Avastin through Pharmacare as of Tuesday.

The treatment is already covered for people living with wet age-related macular degeneration, a condition that can cause vision loss.

A spokesman at the department says the expanded coverage will cost $1 million and affect about 700 people who are part of the seniors, family or Community Services Pharmacare programs.

Diabetic macular edema causes fluid to leak into the eye, resulting in blindness, while retinal vein occlusion is caused by restricted blood supply to the eye, and may also lead to blindness.

The treatments are available through hospital-based clinics and retinal specialists, but Glavine says they may be expanded to other sites across Nova Scotia.


Comments


NOTE: To post a comment in the new commenting system you must have an account with at least one of the following services: Disqus, Facebook, Twitter, Yahoo, OpenID. You may then login using your account credentials for that service. If you do not already have an account you may register a new profile with Disqus by first clicking the "Post as" button and then the link: "Don't have one? Register a new profile".

The Yorkton This Week welcomes your opinions and comments. We do not allow personal attacks, offensive language or unsubstantiated allegations. We reserve the right to edit comments for length, style, legality and taste and reproduce them in print, electronic or otherwise. For further information, please contact the editor or publisher, or see our Terms and Conditions.

blog comments powered by Disqus


Quick Vote

Survey results are meant for general information only, and are not based on recognised statistical methods.


Markets





LOG IN



Lost your password?